OBJECTIVE: To determine if low disease activity state (LDAS)/remission predicts a better health-related quality of life (HRQoL). METHODS: Patients with systemic lupus erythematosus from a single center and having completed at least 2 visits were included. Visits were performed every 6 months. HRQoL was measured with the LupusQoL questionnaire. The definition of remission included a Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score of 0, prednisone daily dosage of ≤5 mg/day, and immunosuppressive drugs on maintenance dose. LDAS was defined as a SLEDAI-2K score of ≤4, prednisone daily dosage of ≤7.5 mg/day, and immunosuppressive drugs as maintenance therapy. For these analyses, remission and LDAS were combined as one variable. Generalized estimating equations were calculated, using as the outcome 1 of each of the 8 components of the LupusQoL questionnaire in the subsequent visit and the activity state in the previous visit. Multivariable models were adjusted for possible confounders. RESULTS: A total of 243 patients were included. During the follow-up, 590 visits (61.6%) were categorized as LDAS/remission. LDAS/remission predicted a better HRQoL in the components of physical health (B = 4.17 [95% confidence interval (95% CI) 1.20, 7.14]; P = 0.006), pain (B = 6.47 [95% CI 3.18, 9.76]; P < 0.001), planning (B = 4.97 [95% CI 1.43, 8.52]; P = 0.006), burden to others (B = 4.12 [95% CI 0.24, 8.01]; P = 0.037], emotional health (B = 4.50 [95% CI 1.56, 7.44]; P = 0.003), and fatigue (B = 3.25 [95% CI 0.04, 6.47]; P = 0.048). CONCLUSION: Being in LDAS/remission predicts a better HRQoL, especially in the components of physical health, pain, planning, burden to others, emotional health, and fatigue.
OBJECTIVE: To determine if low disease activity state (LDAS)/remission predicts a better health-related quality of life (HRQoL). METHODS:Patients with systemic lupus erythematosus from a single center and having completed at least 2 visits were included. Visits were performed every 6 months. HRQoL was measured with the LupusQoL questionnaire. The definition of remission included a Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score of 0, prednisone daily dosage of ≤5 mg/day, and immunosuppressive drugs on maintenance dose. LDAS was defined as a SLEDAI-2K score of ≤4, prednisone daily dosage of ≤7.5 mg/day, and immunosuppressive drugs as maintenance therapy. For these analyses, remission and LDAS were combined as one variable. Generalized estimating equations were calculated, using as the outcome 1 of each of the 8 components of the LupusQoL questionnaire in the subsequent visit and the activity state in the previous visit. Multivariable models were adjusted for possible confounders. RESULTS: A total of 243 patients were included. During the follow-up, 590 visits (61.6%) were categorized as LDAS/remission. LDAS/remission predicted a better HRQoL in the components of physical health (B = 4.17 [95% confidence interval (95% CI) 1.20, 7.14]; P = 0.006), pain (B = 6.47 [95% CI 3.18, 9.76]; P < 0.001), planning (B = 4.97 [95% CI 1.43, 8.52]; P = 0.006), burden to others (B = 4.12 [95% CI 0.24, 8.01]; P = 0.037], emotional health (B = 4.50 [95% CI 1.56, 7.44]; P = 0.003), and fatigue (B = 3.25 [95% CI 0.04, 6.47]; P = 0.048). CONCLUSION: Being in LDAS/remission predicts a better HRQoL, especially in the components of physical health, pain, planning, burden to others, emotional health, and fatigue.
Authors: Ronald F van Vollenhoven; George Bertsias; Andrea Doria; David Isenberg; Eric Morand; Michelle A Petri; Bernardo A Pons-Estel; Anisur Rahman; Manuel Francisco Ugarte-Gil; Alexandre Voskuyl; Laurent Arnaud; Ian N Bruce; Ricard Cervera; Nathalie Costedoat-Chalumeau; Caroline Gordon; Frédéric A Houssiau; Marta Mosca; Matthias Schneider; Michael M Ward; Graciela Alarcon; Martin Aringer; Anka Askenase; Sang-Cheol Bae; Hendrika Bootsma; Dimitrios T Boumpas; Hermine Brunner; Ann Elaine Clarke; Cindy Coney; László Czirják; Thomas Dörner; Raquel Faria; Rebecca Fischer; Ruth Fritsch-Stork; Murat Inanc; Søren Jacobsen; David Jayne; Annegret Kuhn; Bernadette van Leeuw; Maarten Limper; Xavier Mariette; Sandra Navarra; Mandana Nikpour; Marzena Helena Olesinska; Guillermo Pons-Estel; Juanita Romero-Diaz; Blanca Rubio; Yehuda Schoenfeld; Eloisa Bonfá; Josef Smolen; Y K Onno Teng; Angela Tincani; Michel Tsang-A-Sjoe; Carlos Vasconcelos; Anne Voss; Victoria P Werth; Elena Zakharhova; Cynthia Aranow Journal: Lupus Sci Med Date: 2021-11
Authors: Manuel Francisco Ugarte-Gil; Rocio Violeta Gamboa-Cardenas; Cristina Reátegui-Sokolova; Victor Román Pimentel-Quiroz; Mariela Medina; Claudia Elera-Fitzcarrald; Francisco Zevallos; Cesar Augusto Pastor-Asurza; Federico Zazzetti; Chetan S Karyekar; Graciela S Alarcón; Risto Alfredo Perich-Campos Journal: Lupus Sci Med Date: 2022-03
Authors: Elena Elefante; Chiara Tani; Chiara Stagnaro; Viola Signorini; Alice Parma; Linda Carli; Dina Zucchi; Francesco Ferro; Marta Mosca Journal: Arthritis Res Ther Date: 2020-10-14 Impact factor: 5.156